Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Emerg Drugs. 2012 Dec;17(4):571-82. doi: 10.1517/14728214.2012.739606. Epub 2012 Nov 5.

Emerging cell-cycle inhibitors for pancreatic cancer therapy.

Author information

  • 1Mercy Cancer Center, Department of Medical Oncology, 1220 Hall street, Ardmore, OK, USA.

Abstract

INTRODUCTION:

Patients with pancreatic cancer (PC) present with advanced disease that is lethal and notoriously difficult to treat. The research focused initially on combining cytotoxic therapies with gemcitabine, and over the past decade, a large number of studies have been published that aimed to target the molecular abnormalities implicated in pancreatic tumor growth.

AREAS COVERED:

The cell cycle is a tightly regulated series of events that governs cell replication and division. Deregulation of cell cycle kinases have been implicated in PC tumorigenesis. In this review, we discuss the potential and limitations of current cyclin-kinase inhibitors. We also summarize progress in evaluating other mitotic kinase inhibitors and novel cell-cycle kinase inhibitors as potential therapeutic agents in PC.

EXPERT OPINION:

While the successful development and approval of cell-cycle inhibitors for PC therapy remains unresolved, pre-clinical identification of resistant mechanisms would help design better early- phase clinical trials where relevant combinations may be evaluated prior to Phase II testing. The authors believe that cell-cycle kinases are important anti-cancer targets that operate in collaboration with other oncogenes intimately involved in uncontrolled tumor proliferation and by providing a unique, targeted, and complimentary anti-cancer mechanism, expand the available armamentarium against PC.

PMID:
23126234
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk